Trump administration will fund new research on controversial psychedelic drug ibogaine

Federal officials on Thursday announced new funding to explore the medical potential of ibogaine, a controversial psychedelic drug championed by veterans, conservative lawmakers and podcasters aligned with President Donald Trump.

Health Secretary Robert F. Kennedy Jr. said his department is awarding up to $4.9 million to prepare for the first U.S. studies of ibogaine for post-traumatic stress disorder, a hard-to-treat condition linked to higher suicide and substance abuse rates among veterans.

The money will not go directly to patient research, Kennedy said, but to lay the groundwork needed to manufacture, dose and design studies of the drug.

Ibogaine is made from a shrub native to West Africa. It can cause intense hallucinations, nausea, vomiting, tremors and sometimes deadly irregular heart rhythms. Ibogaine is currently illegal, in the same ultra-restrictive class as LSD, ecstasy and most other psychedelic drugs.

Veterans organizations and psychedelic advocates contend that ibogaine has great promise for intractable conditions such as PTSD, severe depression and opioid addiction. U.S. research on the drug has essentially been frozen for decades due to ibogaine’s restricted status.

Kennedy said the government will receive data and treatment guidance from Beond Inc., a Texas-based company that has treated more than 3,000 patients with ibogaine in Mexico, where the drug is not illegal.

“That is going to allow us to dramatically accelerate the clinical trial process,” Kennedy said. “We’re going to have, I think, a record drug approval process.”

Additional funding awards may explore ibogaine’s use for addiction, he said.

Veterans Affairs Secretary Doug Collins, who joined Kennedy for the announcement, said the collaborative effort would focus first on safety and “best-in-class research.”

“For veterans living with PTSD, we owe them both urgency and the best science we can produce,” Collins said.

Kennedy and Collins have previously voiced support for the potential of psychedelics, citing the experiences of veterans who have traveled abroad for therapy with ibogaine and other mind-altering substances.

Thursday’s announcement was previewed in April, when Trump signed an executive order directing federal agencies to speed up review and research of psychedelics that could help with mental health conditions.

Three applications for psychedelics are pending review at the Food and Drug Administration. They include the first potential medicines made from psilocybin, the active ingredient in magic mushrooms, and MDMA, also called ecstasy. Decisions on those drugs could come within weeks or months.

Because of its safety risks, ibogaine research has moved more slowly.

The little data currently available mostly comes from patients who have traveled to Mexico or other countries where ibogaine is not heavily regulated. Ibogaine clinics typically charge $10,000 to $20,000 for one course of treatment, which often involves monitoring of a patient’s heart readings while emergency medical workers are on standby.

Trump’s order on psychedelics came after podcaster Joe Rogan said he texted Trump about ibogaine, which he repeatedly has discussed on his show. According to Rogan, the president quickly responded: “Sounds great. Do you want FDA approval? Let’s do it.”

___

The Associated Press’ health and science coverage receives financial support from the AP Fund for Journalism and private foundations. AP is solely responsible for all content. Find AP’s standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.